Research Progress on Relationship between Gut Microbiota and Pemphigus Vulgaris

doi:10.13701/j.cnki.kqyxyj.2026.01.003

Abstract

Abstract: Environmental factors play a pivotal role in the pathogenesis of pemphigus vulgaris (PV). As a significant environmental component, the gut microbiota has been increasingly recognized for its influence on the progression of various autoimmune diseases. Interventions targeting the gut microbiota have emerged as a novel therapeutic strategy for autoimmune disorders. Recent studies have demonstrated a strong correlation between gut dysbiosis and the development and progression of PV. This review comprehensively examines the role of gut microbiota in PV pathogenesis, potential mechanisms through which microbiota dysregulation influences PV, and potential therapeutic approaches targeting gut microbiota for PV intervention. The findings provide a theoretical foundation and research directions for elucidating the pathogenesis of PV and exploring innovative treatment strategies.

Key words: pemphigus vulgaris, intestinal microbiota, pathogenesis, microbiota imbalance

ZHAO Can, SHI Jing. Research Progress on Relationship between Gut Microbiota and Pemphigus Vulgaris[J]. Journal of Oral Science Research, 2026, 42(1): 12-16.

References

[1] 陈谦明.口腔黏膜病学[M].第5版.北京:人民卫生出版社,2020.70-73.
[2] Porro AM, Seque CA, Ferreira M, et al. Pemphigus vulgaris[J]. An Bras Dermatol, 2019, 94(3):264-278.
[3] Kianfar N, Daneshpazhooh M, Lehman JS. Pemphigus vulgaris[J]. Mayo Clin Proc, 2024, 99(4):607-609.
[4] Davis G, Hathway R, Shipley D, et al. The management of pemphigus vulgaris and mucous membrane pemphigoid in a joint oral medicine and dermatology clinic: a five-year narrative review[J]. Br Dent J, 2024, 236(4):311-316.
[5] Wang X, Yuan W, Yang C, et al. Emerging role of gut microbiota in autoimmune diseases[J]. Front Immunol, 2024,15:1365554.
[6] Tan S, Santolaya JL, Wright TF, et al. Interaction between the gut microbiota and colonic enteroendocrine cells regulates host metabolism[J]. Nat Metab, 2024, 6(6):1076-1091.
[7] McCallum G, Tropini C. The gut microbiota and its biogeography[J]. Nat Rev Microbiol, 2024, 22(2):105-118.
[8] Yang S, Liu H, Liu Y. Advances in intestinal epithelium and gut microbiota interaction[J]. Front Microbiol, 2025,16:1499202.
[9] Li X, Li J, Ji J, et al. Gut microbiota modification by diosgenin mediates antiepileptic effects in a mouse model of epilepsy[J]. J Neurochem, 2024, 168(12):3982-4000.
[10] 郭子瑜.天疱疮患者的肠道菌群改变与代谢组学特征及其关联研究[D].中南大学,2023.
[11] 黄书莉.寻常型天疱疮患者与健康对照组肠道菌群及血清细胞因子的差异性研究[D].西南医科大学,2019.
[12] Lin L, Zhang K, Xiong Q, et al. Gut microbiota in pre-clinical rheumatoid arthritis: From pathogenesis to preventing progression[J]. J Autoimmun, 2023, 141:103001.
[13] Huang S, Mao J, Zhou L, et al. The imbalance of gut microbiota and its correlation with plasma inflammatory cytokines in pemphigus vulgaris patients[J]. Scand J Immunol, 2019, 90(3):e12799.
[14] Guo Z, Yiu N, Hu Z, et al. Alterations of fecal microbiome and metabolome in pemphigus patients[J]. J Autoimmun, 2023, 141:103108.
[15] Wang Y, Xia X, Zhou X, et al. Association of gut microbiome and metabolites with onset and treatment response of patients with pemphigus vulgaris[J]. Front Immunol, 2023, 14:1114586.
[16] Li SZ, Wu QY, Fan Y, et al. Gut microbiome dysbiosis in patients with pemphigus and correlation with pathogenic autoantibodies[J]. Biomolecules, 2024, 14(7):880.
[17] Arnaut N, Ciurea CN, Cighir A. The gut-skin axis: Investigating gut microbiota dysbiosis in pemphigus and bullous pemphigoid[J]. Acta Marisiensis-Seria Medica, 2024, 70(2668-7755):105-111.
[18] Christovich A, Luo XM. Gut microbiota, leaky gut, and autoimmune diseases[J]. Front Immunol, 2022,13:946248.
[19] Vedantam G, Viswanathan VK, Roxas JL, et al. Enteropathogenic Escherichia coli EspH-mediated Rho GTPase inhibition results in desmosomal perturbations[J]. Cell Mol Gastroenterol Hepatol, 2018, 6(2):163-180
[20] Ren X, Yang D, Yang Z, et al. Prevalence and antimicrobial susceptibility of foodborne pathogens from raw livestock meat in China, 2021[J]. Microorganisms, 2024, 12(11):2157.
[21] Mann ER, Lam YK, Uhlig HH. Short-chain fatty acids: linking diet, the microbiome and immunity[J]. Nat Rev Immunol, 2024, 24(8):577-595.
[22] Maglie R, Baldi S, Nannini G, et al. Alterations of circulating free fatty acids in patients with pemphigus vulgaris[J]. Exp Dermatol, 2024, 33(3):e15063.
[23] Recharla N, Geesala R, Shi XZ. Gut microbial metabolite butyrate and its therapeutic role in inflammatory bowel disease: A literature review[J]. Nutrients, 2023, 15(10):2275.
[24] Didona D, Scarsella L, Hudemann C, et al. Type 2 T-cell responses against distinct epitopes of the desmoglein 3 ectodomain in pemphigus vulgaris[J]. J Invest Dermatol, 2024, 144(2):263-272.
[25] He R, Chen J, Zhao Z, et al. T-cell activation Rho GTPase-activating protein maintains intestinal homeostasis by regulating intestinal T helper cells differentiation through the gut microbiota[J]. Front Microbiol, 2023, 13:1030947.
[26] Roy U, de Oliveira RS, Galvez E, et al. Induction of IL-22-producing CD4⁺ T cells by segmented filamentous bacteria independent of classical Th17 cells[J]. Front Immunol, 2021, 12:671331.
[27] Gu Y, Zhang W, Zhao W, et al. Investigating causal relationships between the gut microbiota and inflammatory skin diseases: A Mendelian randomization study[J]. Australas J Dermatol, 2024, 65(4):319-327.
[28] Kajdas AA, Zebrowska A, Zalewska-Janowska A, et al. The role of nutrition in thepathogenesis and treatment of autoimmune bullous diseases-A narrative review[J]. Nutrients, 2024, 16(22):3961.
[29] Geng N, Li Y, Zhang Y, et al. Effects of modified dietary fiber from fresh corn bracts on obesity and intestinal microbiota in high-fat-diet mice[J]. Molecules, 2023, 28(13):4949.
[30] Ikeda T, Nishida A, Yamano M, et al. Short-chain fatty acid receptors and gut microbiota as therapeutic targets in metabolic, immune, and neurological diseases[J]. Pharmacol Ther, 2022, 239:108273.
[31] Tahri S, Elloumi N, Khabou B, et al. Exploring the role of vitamin D-VDR pathway in pemphigus foliaceous: a novel perspective on disease pathogenesis[J]. Arch Dermatol Res, 2024, 316(7):449.
[32] Stoj V, Lu J. Nutrition and bullous diseases[J]. Clin Dermatol, 2022, 40(2):156-165.
[33] Franks SJ, Dunster JL, Carding SR, et al. Modelling the influence of vitamin D and probiotic supplementation on the microbiome and immune response[J]. Math Med Biol, 2024, 41(4):304-345.
[34] Lopes CM, de Jesus MC, Duarte AP, et al. Probiotics and prebiotics for the treatment of irritable bowel syndrome-A narrative review[J]. J Clin Med, 2024, 13(21):6337.
[35] Ge Y, Sun H, Xu L, et al. The amelioration of alcohol-induced liver and intestinal barrier injury by Lactobacillus rhamnosus Gorbach-Goldin (LGG) is dependent on interleukin 22 (IL-22) expression[J]. Bioengineered, 2022, 13(5):12650-12660.
[36] Bocchio F, Mancabelli L, Milani C, et al. Compendium of Bifidobacterium-based probiotics: characteristics and therapeutic impact on human diseases[J]. Microbiome Res Rep, 2025, 4(1):2.
[37] Noguera-Fernandez N, Candela-Gonzalez J, Orenes-Pinero E. Probiotics, prebiotics, fecal microbiota transplantation, and dietary patterns in inflammatory bowel disease[J]. Mol Nutr Food Res, 2024, 68(18):e2400429.
[38] Zhanel GG, Keynan R, Keynan Y, et al. The role of fecal microbiota transplantation (FMT) in treating patients with multiple sclerosis[J]. Expert Rev Neurother, 2023, 23(10):921-930.
[39] Yang R, Chen Z, Cai J. Fecal microbiota transplantation: Emerging applications in autoimmune diseases[J]. J Autoimmun, 2023, 141:103038.